At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DRTS Alpha Tau Medical
Post-Mkt 08-26 17:08:08 EDT
14.96
+0.26
+1.77%
盘后15.00
+0.04+0.27%
16:57 EDT
High15.00Low14.58Vol431.70K
Open14.70D1 Closing14.70Amplitude2.86%
Mkt Cap1.38BTradable Cap954.36MTotal Shares92.33M
T/O6.44MT/O Rate0.68%Tradable Shares63.79M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Top Executive Makes Notable Move in Alpha Tau Medical’s Insider Activity
TIPRANKS  ·  08-26 10:03
Top Executive Makes Notable Move in Alpha Tau Medical’s Insider Activity
Alpha Tau Medical CFO Raphi Levy Disposes of $43,058.04 in Common Shares
Reuters  ·  08-25 22:34
Alpha Tau Medical CFO Raphi Levy Disposes of $43,058.04 in Common Shares
Nano Dimension Appoints Oramed CEO Nadav Kidron to Board to Chair Strategy, Capital Allocation Committee
Reuters  ·  08-17
Nano Dimension Appoints Oramed CEO Nadav Kidron to Board to Chair Strategy, Capital Allocation Committee
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
THOMSON REUTERS  ·  08-17
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
Top Executive Makes Notable Move With Alpha Tau Medical Stock
TIPRANKS  ·  08-13
Top Executive Makes Notable Move With Alpha Tau Medical Stock
Alpha Tau Medical CFO Raphi Levy Disposes of 17,730 Shares for $248,037.74
Reuters  ·  08-13
Alpha Tau Medical CFO Raphi Levy Disposes of 17,730 Shares for $248,037.74
Alpha Tau Medical is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  08-11
Alpha Tau Medical is Maintained at Buy by HC Wainwright & Co.
Alpha Tau price target raised to $16 from $15 at H.C. Wainwright
TIPRANKS  ·  08-11
Alpha Tau price target raised to $16 from $15 at H.C. Wainwright
Alpha Tau Medical Ltd. : H.c. Wainwright Raises Target Price to $16 from $15
THOMSON REUTERS  ·  08-11
Alpha Tau Medical Ltd. : H.c. Wainwright Raises Target Price to $16 from $15
U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics
Reuters  ·  08-11
U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics
Alpha Tau Medical Updates Investors With H1 2026 Financials in New Form 6-K Filing
TIPRANKS  ·  08-11
Alpha Tau Medical Updates Investors With H1 2026 Financials in New Form 6-K Filing
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Benzinga Earnings  ·  08-11
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Alpha Tau FY26 H1 Net Loss More than Doubled to $68.8 Million
Reuters  ·  08-11
Alpha Tau FY26 H1 Net Loss More than Doubled to $68.8 Million
Press Release: Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones  ·  08-11
Press Release: Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Medical Registers for Dual Listing on Tel Aviv Stock Exchange, Keeps NASDAQ Listing
Reuters  ·  08-10
Alpha Tau Medical Registers for Dual Listing on Tel Aviv Stock Exchange, Keeps NASDAQ Listing
Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study
Simply Wall St.  ·  07-26
Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study
Alpha Tau Medical Price Target Maintained with a $15.00/share by HC Wainwright & Co.
Dow Jones  ·  07-23
Alpha Tau Medical Price Target Maintained with a $15.00/share by HC Wainwright & Co.
Alpha Tau Medical Notifies Availability of Press Release on Alpha Dart-pembrolizumab Head and Neck Cancer Data
Reuters  ·  07-21
Alpha Tau Medical Notifies Availability of Press Release on Alpha Dart-pembrolizumab Head and Neck Cancer Data
Alpha Tau Medical - no Serious Alpha Dart-associated Adverse Events; Only Two Grade 1 Events Reported
THOMSON REUTERS  ·  07-21
Alpha Tau Medical - no Serious Alpha Dart-associated Adverse Events; Only Two Grade 1 Events Reported
Alpha Tau Medical - Median Overall Survival 18.2 Months, Median Progression-free Survival 5.4 Months with Alpha Dart Plus Pembrolizumab
THOMSON REUTERS  ·  07-21
Alpha Tau Medical - Median Overall Survival 18.2 Months, Median Progression-free Survival 5.4 Months with Alpha Dart Plus Pembrolizumab

Introduction

Company Name.
Alpha Tau Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Issue price:
--